SG Americas Securities LLC Invests $250,000 in Miragen Therapeutics, Inc. (MGEN) Stock
SG Americas Securities LLC acquired a new position in shares of Miragen Therapeutics, Inc. (NASDAQ:MGEN) in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 27,283 shares of the medical research company’s stock, valued at approximately $250,000. SG Americas Securities LLC owned about 0.13% of Miragen Therapeutics at the end of the most recent reporting period.
Separately, Russell Investments Group Ltd. bought a new position in Miragen Therapeutics during the 3rd quarter worth $147,000. 22.64% of the stock is currently owned by institutional investors and hedge funds.
Miragen Therapeutics, Inc. (NASDAQ MGEN) opened at $8.96 on Thursday. The company has a debt-to-equity ratio of 0.04, a current ratio of 7.11 and a quick ratio of 7.11. Miragen Therapeutics, Inc. has a 12-month low of $4.65 and a 12-month high of $18.00.
A number of brokerages have issued reports on MGEN. Chardan Capital reiterated a “buy” rating and set a $29.00 price target on shares of Miragen Therapeutics in a research report on Monday, October 16th. Zacks Investment Research lowered Miragen Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, October 24th. ValuEngine lowered Miragen Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, August 23rd. Finally, Wedbush reiterated a “buy” rating and set a $19.00 price target on shares of Miragen Therapeutics in a research report on Friday, December 1st. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company. Miragen Therapeutics presently has an average rating of “Buy” and a consensus price target of $18.67.
Miragen Therapeutics Company Profile
Signal Genetics, Inc is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company’s diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test.
Receive News & Ratings for Miragen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miragen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.